Canada: Supreme Court Of Canada Decides Transfer Pricing Case - Canada v. GlaxoSmithKline Inc.

Last Updated: October 25 2012
Article by Christopher Steeves

In its recently-released judgement in Canada v. GlaxoSmithKline Inc.1 the Supreme Court of Canada has considered transfer pricing tax issues for the first time.  This decision is important to multi-national enterprises ("MNEs") because the Supreme Court makes it clear that Canadian courts have broad scope to determine whether prices used for the transfer of property or services between a Canadian resident taxpayer and non-arm's length non-residents are reasonable.  The Supreme Court agreed with the Federal Court of Appeal in overturning the original decision of the Tax Court of Canada (the "Tax Court") to essentially confirm the income tax reassessment of GlaxoSmithKline Inc. ("Glaxo Canada") issued by the Minister of National Revenue (the "Minister"). The Tax Court held that the reasonableness of transfer pricing should be determined on a strict transaction-by-transaction basis and other agreements or transactions entered into by the parties should be ignored.  However, the Supreme Court concluded that if other transactions are relevant in determining whether transfer pricing is reasonable, these transactions should be taken into account.  In this case, the existence of both a licence agreement and a supply agreement between Glaxo Canada and certain affiliated non-resident corporations was pertinent to the analysis.

Although the Supreme Court dismissed the Crown's appeal of the Federal Court of Appeal decision, it did not determine whether the transfer pricing used by Glaxo Canada was reasonable in the circumstances. Instead, the Supreme Court remitted the matter back to the Tax Court for redetermination based on the Supreme Court's guidance.  As a result, Glaxo Canada's victory at the Supreme Court is tempered by the reality that it still must prove to the Tax Court that the prices it paid to its non-resident affiliates are not greater than what would have been reasonable in the circumstances if they were dealing with each other at arm's length.


The Minister reassessed Glaxo Canada for tax years 1990 to 1993, arguing that Glaxo Canada had overpaid its Swiss affiliate Adechsa S.A. ("Adechsa") under a supply agreement for ranitidine. Ranitidine is the active ingredient in the ulcer medication Zantac, which was manufactured, marketed and distributed by Glaxo Canada under a licence agreement with Glaxo Canada's parent, Glaxo Group Ltd. ("Glaxo Group"). During the years at issue, Glaxo Canada had paid Adechsa between $1,512 and $1,651 per kilogram of ranitidine. The Minister used subsection 69(2) (a precursor to subsection 247(2)) of the Income Tax Act ("ITA") 2 to argue that this transfer pricing was unreasonable based on the fact that other Canadian pharmaceutical companies were paying, at a maximum, just over $300 per kilogram to their non-affiliated suppliers for generic versions of the drug.

Under a separate licence agreement, Glaxo Canada was granted certain intellectual property rights, including the right to sell the medication under the Zantac trademark. In return, Glaxo Canada paid an annual royalty of 6% of its net sales to Glaxo Group.

The Lower Courts

The Tax Court3 accepted the Minister's approach and compared the Glaxo Canada ranitidine purchase transaction to a ranitidine purchase transaction made by two generic pharmaceutical companies and concluded that the arm's length pricing was marginally higher than the highest generic drug pricing.  The Tax Court ordered the Minister to issue an income tax reassessment of Glaxo Canada on the basis that payments to Adechsa in excess of the arm's length transfer price were not deductible by Glaxo Canada in computing its income for Canadian tax purposes.  In addition, the Tax Court ordered the Minister to assess Glaxo Canada under Part XIII of the ITA on the basis that the excess amounts paid to Adechsa were deemed dividends subject to Canadian non-resident withholding tax.

The Federal Court of Appeal4 overturned the Tax Court decision and sent the case back for re-hearing on the basis that the Tax Court judge had erred in not taking into account all the relevant circumstances surrounding the transaction. Such circumstances include the fact that, because of the licence agreement, Glaxo Canada could command a premium for Zantac over the generic ranitidine drugs, and hence, would be willing to pay more for the means by which to sell the non-generic version.

The Supreme Court granted the Crown's request for leave to appeal. Glaxo Canada also sought (and received) leave to cross-appeal the decision of the Federal Court of Appeal in respect of the order referring the matter back to the Tax Court for determination of the reasonable arm's length transfer prices.

The Supreme Court Decision

In the unanimous decision of the Supreme Court, Justice Rothstein's reasons support expansion of the factors that may be taken into account when determining the reasonableness of transfer pricing.  Since reasonableness is relative: one must compare the amount paid by the entity to its affiliate to that which would have been reasonable had the parties been dealing at arm's length in similar economic circumstances. In order to assess this hypothetical amount, however, a court should not be restricted to considering a particular transaction in isolation if the facts do not warrant such a narrow inquiry.  On these facts, for example, any definition of reasonableness would need to account for agreements between the parties (such as the licence agreement) outside the transaction for the purchase of ranitidine itself.

Noting that subsection 69(2) of the ITA does not define "reasonable", the Supreme Court considered the reliance by the lower courts on the 1995 OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (the "OECD Guidelines").  The Supreme Court cautions that the OECD Guidelines are "not controlling as if they were Canadian statute"; determination ultimately rests with the provisions of the ITA.  Justice Rothstein acknowledged that the OECD Guidelines suggest four methods for determining the reasonableness of a transfer price: (i) the comparable uncontrolled price ("CUP") method; (ii) the cost plus method; (iii) the resale-price method; and (iv) the transactional net margin method. The Supreme Court made no definitive determination as to the appropriateness of any of these four methods in the circumstances, leaving any determination for re-hearing at the Tax Court.

Justice Rothstein rejected the strict application of a "transaction-by-transaction" approach stating: "while a transaction-by-transaction approach may be ideal, [the OECD Guidelines] themselves recognize that it is not appropriate in all cases.5 Furthermore (and again quoting the OECD Guidelines), Justice Rothstein noted that "an arm's length comparator is only useful if economically-relevant characteristics... [are] sufficiently comparable." 6

The Supreme Court concluded that the licence agreement between Glaxo Group and Glaxo Canada must be taken into account to determine whether the transfer price for the ranitidine purchase is reasonable. It was because of the licence agreement that Glaxo Canada was purchasing its ranitidine from its parent's preferred source: Adechsa. Without the licence agreement, Glaxo Canada would not have been able to manufacture, market or distribute the ranitidine it received. Also, the licence agreement allowed Glaxo Canada to avoid the risk involved with product development. The Supreme Court concluded that these rights and benefits "could not be irrelevant" in an assessment of whether the higher price was reasonable as compared to generic peers. 7 However, the Supreme Court stopped short of determining whether the transfer pricing was, in fact, reasonable.

The Supreme Court offered the following guidance for the Tax Court in redetermining whether the transfer prices in this case are reasonable. First, as transfer pricing "to use the words of the [OECD Guidelines]... 'is not an exact science'," "reasonable amount" should be interpreted as "reasonable range."8 If the transfer price used Glaxo Canada is not within this reasonable range, then "the court might select a point within a range it considers reasonable in the circumstances based on an average, median, mode or other appropriate statistical measure, having regard to the evidence that the court found to be relevant."9  Second, the Tax Court must look at the respective roles of Glaxo Canada and Glaxo Group to determine whether a higher price was justified on the basis of compensation for intellectual property rights. 10 Third, both the interests of Glaxo Canada and Glaxo Group must be considered by the Tax Court having regard to their independent interests.11 Lastly, the fact that arm's length parties have purchased ranitidine from Glaxo Group suppliers (rather than from a generic source) indicates that some amount of price increase will be justified.12

In dismissing the cross-appeal, the Supreme Court held that while Glaxo Canada had successfully demolished the Minister's assumption that the transfer price paid to Adechsa for the purchase of ranitidine should not be greater than the prices paid for ranitidine by the Canadian generic pharmaceutical companies, it had not demolished the Minister's assumption that the amounts paid to Adechsa were unreasonable.  On this basis, the Supreme Court remitted the matter to the Tax Court for redetermination. 13

Fasken Martineau Commentary

While novel to the extent that the Supreme Court has never considered a transfer pricing case or the OECD Guidelines, it may be many more months before this case will be concluded and the extent to which the outcome may be considered a "victory" for Glaxo Canada.

As the Supreme Court sent the case back to the Tax Court for redetermination, both the Minister and Glaxo Canada are, in some ways, back to where they started. The case at first instance was lengthy and, as has been the recent trend in tax litigation, required the testimony of tax experts on both sides, leading to lengthy transcripts. This testimony will need to be re-visited and re-assessed and new testimony may be introduced. During the initial trial before the Tax Court, Associate Chief Justice Rip (now Chief Justice) favoured the testimony of the Minister's expert, Dr. Jack Mintz, citing that the testimony of the Glaxo Canada experts was unreasonable. With a broadened definition of what may be considered in the reasonableness assessment, it is not clear that on re-hearing the conclusion will be the same.

While the Supreme Court admitted that the purchase price was likely linked to rights under the license agreement, it refused to determine whether some portion of the purchase price for ranitidine was really a royalty payment for Glaxo Canada's licence of the intellectual property of its UK parent. 14 The Supreme Court points out that if it is the case that part of this transaction can be characterized as a Canadian entity paying a royalty to a non-resident, there would have to be "consistency" between this characterization and Glaxo Canada's obligations with respect to withholding tax under Part XIII of the Income Tax Act.15 To guide the Tax Court, the Supreme Court refers to three specific provisions regarding royalties under the licence agreement.16

It is worth noting that even if the Tax Court concluded that some portion of the payments to Adechsa were on account of intellectual property rights, since the principal focus of this appeal is the deductibility of the payments such "embedded" royalties should still be deductible by Glaxo Canada.

These comments are also interesting from a procedural standpoint. While Justice Rothstein states that Glaxo Canada's Part XIII tax position may be addressed by the parties and considered by the Tax Court judge as part of the redetermination, it is unclear whether this concept of embedded royalties for use of intellectual property has been raised previously by the Minister in these proceedings. Query whether it is open to the Minister to do so now at this late stage.

Generally, the Supreme Court's requirement for a fact-driven, holistic approach to assessing the reasonableness of transfer pricing will give MNEs some leeway in structuring arrangements within their corporate groups.  Based on Justice Rothstein's reasons, it seems clear that the OECD Guidelines are not determinative for purposes of interpreting the transfer pricing rules in the ITA.  In fact the only statement from the OECD Guidelines that the Supreme Court appears to have confirmed was that determining arm's length transfer prices is not an exact science.  As a result, even though the Tax Court favoured the CUP method of transfer pricing analysis, the Supreme Court indicated that this may not be the best method for analysis in this case, due to its narrow focus on particular transactions.  Since the Supreme Court declined to elaborate further, the door appears to be open to any, or none, of the four OECD methods being acceptable for determining a reasonable transfer price, depending on the circumstance of the particular taxpayer as compared to that taxpayer's economic comparator group.


1 2012 SCC 52 ("GlaxoSmithKline").

2 Income Tax Act R.S.C. 1985 c.1 (5th Supp). It is worth noting that unlike the old subsection 69(2), subsection 247(2) does not contain a requirement that the pricing be "reasonable in the circumstances", only that the terms and conditions of the transaction or series of transactions between the parties "had been those that would have been made between persons dealing at arm's length."

3 GlaxoSmithKline Inc. v. The Queen, 2008 TCC 324, 2008 D.T.C. 3957.

4 GlaxoSmithKline Inc. v. Canada, 2010 FCA 201, 405 N.R. 307.

5 GlaxoSmithKline at para 40.

6 Ibid. at para 42.

7 Ibid. at para 52.

8 Ibid. at para 61.

9 Ibid, at para. 61.

10 Ibid. at para 62.

11 Ibid. at para 63.

12 Ibid. at para 64.

13 Ibid. at para 74.

14 Ibid. at para 57.

15 Ibid. at para 57.

16 Ibid. at para 55.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.